M S Lo Piccolo1, N K Cheung, I Y Cheung. 1. Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Abstract
BACKGROUND: Neuroblastomas (NBs) almost ubiquitously express the ganglioside GD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular marker of NB. METHODS: Seventy-seven NB tumor tissues of all stages, 5 NB cell lines, and 26 normal bone marrows (BMs) and peripheral blood (PBL) samples, as well as 26 non-NB remission-BMs were analyzed for the expression of GD2 synthase by a highly sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) and chemiluminescence detection. One hundred fifty-two NB BMs were tested and comparisons were made among three independent detection techniques, namely GD2 synthase RT-PCR, immunofluorescence (IF), and histology (HIST). RESULTS: GD2 synthase transcript was present in 5 of 5 cell lines and in 77 of 77 tumors tested. Among 116 marrows that were positive by at least 1 of the 3 methods, 78% were detectable by GD2 synthase, 68% by IF, and 46% by HIST. Seventy-six percent of positive BMs that were obtained during treatment and follow-up had GD2 synthase expression, whereas only 29% were HIST positive. Correlation between RT-PCR and IF was high (P = 0.001), and positivity by 3 out of 3 methods was strongly correlated with poor survival (P < 0.01). Of note, marrows tested at the time of chemotherapy were positive by at least 2 out of 3 methods and were associated with adverse outcome (P = 0.01). Serial samples (n = 28) in 5 patients demonstrated close agreement between RT-PCR and patient disease status. CONCLUSIONS: The current study found that molecular detection of GD2 synthase transcript in NB BMs may have potential value in detecting rare tumor cells. Copyright 2001 American Cancer Society.
BACKGROUND:Neuroblastomas (NBs) almost ubiquitously express the gangliosideGD2. GD2 synthesis is dependent on the key enzyme GD2 synthase. Thus, GD2 synthase transcript may prove to be a potential molecular marker of NB. METHODS: Seventy-seven NB tumor tissues of all stages, 5 NB cell lines, and 26 normal bone marrows (BMs) and peripheral blood (PBL) samples, as well as 26 non-NB remission-BMs were analyzed for the expression of GD2 synthase by a highly sensitive reverse transcriptase-polymerase chain reaction (RT-PCR) and chemiluminescence detection. One hundred fifty-two NB BMs were tested and comparisons were made among three independent detection techniques, namely GD2 synthase RT-PCR, immunofluorescence (IF), and histology (HIST). RESULTS:GD2 synthase transcript was present in 5 of 5 cell lines and in 77 of 77 tumors tested. Among 116 marrows that were positive by at least 1 of the 3 methods, 78% were detectable by GD2 synthase, 68% by IF, and 46% by HIST. Seventy-six percent of positive BMs that were obtained during treatment and follow-up had GD2 synthase expression, whereas only 29% were HIST positive. Correlation between RT-PCR and IF was high (P = 0.001), and positivity by 3 out of 3 methods was strongly correlated with poor survival (P < 0.01). Of note, marrows tested at the time of chemotherapy were positive by at least 2 out of 3 methods and were associated with adverse outcome (P = 0.01). Serial samples (n = 28) in 5 patients demonstrated close agreement between RT-PCR and patient disease status. CONCLUSIONS: The current study found that molecular detection of GD2 synthase transcript in NB BMs may have potential value in detecting rare tumor cells. Copyright 2001 American Cancer Society.
Authors: Carles Monterrubio; Sonia Paco; Nagore G Olaciregui; Guillem Pascual-Pasto; Monica Vila-Ubach; Maria Cuadrado-Vilanova; M Mar Ferrandiz; Helena Castillo-Ecija; Romina Glisoni; Nataliya Kuplennik; Achim Jungbluth; Carmen de Torres; Cinzia Lavarino; N K V Cheung; Jaume Mora; Alejandro Sosnik; Angel M Carcaboso Journal: J Control Release Date: 2017-04-12 Impact factor: 9.776
Authors: Ilia N Buhtoiarov; Zane C Neal; Jacek Gan; Tatiana N Buhtoiarova; Manish S Patankar; Jennifer A A Gubbels; Jacquelyn A Hank; Brett Yamane; Alexander L Rakhmilevich; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel Journal: J Leukoc Biol Date: 2011-01-19 Impact factor: 4.962
Authors: Nathaniel W Mabe; Min Huang; Guillermo N Dalton; Gabriela Alexe; Daniel A Schaefer; Anna C Geraghty; Amanda L Robichaud; Amy S Conway; Delan Khalid; Marius M Mader; Julia A Belk; Kenneth N Ross; Michal Sheffer; Miles H Linde; Nghi Ly; Winnie Yao; Maria Caterina Rotiroti; Benjamin A H Smith; Marius Wernig; Carolyn R Bertozzi; Michelle Monje; Constantine S Mitsiades; Ravindra Majeti; Ansuman T Satpathy; Kimberly Stegmaier; Robbie G Majzner Journal: Nat Cancer Date: 2022-07-11
Authors: Gabor Méhes; Andrea Luegmayr; Rosa Kornmüller; Ingeborg M Ambros; Ruth Ladenstein; Helmut Gadner; Peter F Ambros Journal: Am J Pathol Date: 2003-08 Impact factor: 4.307